SCHEMBL19637387

SCHEMBL19637387

CCN(CC)c1nc(OCCCN2CCOCC2)nc2c1CCNC2

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTR2A P28223 2/20 0.43
▸ HRH3 Q9Y5N1 5/20 0.41
▸ MAPK1 P28482 2/20 0.40
▸ ALDH1A1 P00352 2/20 0.40
▸ HTR2B P41595 2/20 0.40
▸ CYP1A2 P05177 1/20 0.40
▸ CHRM2 P08172 1/20 0.40
▸ CHRM1 P11229 1/20 0.40
▸ SCN1A P35498 1/20 0.40
▸ KCNH2 Q12809 1/20 0.40
▸ SCN2A Q99250 1/20 0.40
▸ SIGMAR1 Q99720 1/20 0.40
▸ SCN3A Q9NY46 1/20 0.40
▸ USP2 O75604 1/20 0.40
▸ LMNA P02545 1/20 0.40
▸ TLR7 Q9NYK1 1/20 0.38
▸ CYP2D6 P10635 2/20 0.36
▸ CYP3A4 P08684 1/20 0.36
▸ TSHR P16473 1/20 0.35
▸ HRH2 P25021 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19637325 0.80 HTR2C (0.51) HTR2AHRH3MAPK1ALDH1A1HTR2B
SCHEMBL19637165 0.75 HRH3 (0.45) HTR2AHRH3MAPK1ALDH1A1HTR2B
SCHEMBL22994702 0.74 ALDH1A1 (0.41) HTR2AHRH3MAPK1ALDH1A1HTR2B
SCHEMBL21895570 0.74 MAPK1 (0.41) HTR2AHRH3MAPK1ALDH1A1HTR2B
SCHEMBL21315023 0.74 MTOR (0.44) HRH3HTR2BUSP2TLR7KDM4E
SCHEMBL29245850 0.73 MTOR (0.40) HRH3HTR2BUSP2TLR7KDM4E
SCHEMBL19617224 0.73 MTOR (0.40) HRH3HTR2BUSP2TLR7KDM4E
SCHEMBL19617015 0.72 TLR9 (0.44) HRH3USP2TLR7CYP2D6CYP3A4
SCHEMBL22994708 0.72 HTR2A (0.34) HTR2ACHRM2CHRM1
SCHEMBL19636856 0.70 MTOR (0.38) HRH3TLR7CYP2D6CYP3A4MTOR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3458445-B1 KRAS G12C INHIBITORS MIRATI THERAPEUTICS INC (US) 2021-02-17 — — EP disclosed
WO-2017201161-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. (US) 2017-11-23 — — WO disclosed
Send feedback